Article by Dr. Shaw

Dr. Shaw discusses the recent approval of Alectinib and the treatment implications now that there are 3 ALK inhibitors approved by the FDA.

http://www.ascopost.com/issues/january-25-2016/the-evolving-treatment-landscape-of-alk-positive-nsclc/

This entry was posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Imunotherapies, Lung cancer, Potential Treatments, Research. Bookmark the permalink.

Leave a Reply